Back to results
US 2022/0177590 A1Published application
Anti pd-l1 antibody and use thereof
AssigneeRemegen Co., Ltd.
InventorsJianmin FANG, Jing JIANG, Shenjun LI, Guorui ZHAO
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeRemegen Co., Ltd.
InventorsJianmin FANG, Jing JIANG, Shenjun LI, Guorui ZHAO
Estimating the term…
Provided in the present invention is a PD-L1 immunosuppressant, and specifically provided are a monoclonal antibody capable of targeting PD-L1, and nucleotides, combinations of polynucleotides, expression vectors and combinations of expression vectors encoding the antibody. Also provided in the present invention is a conjugate or pharmaceutical composition containing the above-mentioned anti PD-L1 antibody. Further provided in the present invention is the use of the above-mentioned anti PD-L1 antibody, nucleotides, combinations of polynucleotides, expression vectors, combinations of expression vectors, conjugate or pharmaceutical composition in the preparation of a medicament for treating or preventing cancers.
An isolated anti-PD-L1 antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and/or the light chain variable region comprise a CDR sequence identical to that of an antibody defined by the following sequence or obtained by 1-2 amino acid substitutions of the CDR sequence of the antibody defined by the following sequence:
(canceled)
(canceled)
9-12. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.